ArticleDiabetologia2006
Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells.
Article in Diabetologia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- The role of PPARγ in cancer cachexia: friend or foe?Frontiers in endocrinology · 2025Review
- Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes.Journal of diabetes investigation · 2021Review
- Estrogen-related receptor α is involved in angiogenesis and skeletal muscle revascularization in hindlimb ischemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Positioning Metabolism as a Central Player in the Diabetic Heart.Journal of lipid and atherosclerosis · 2020Review
- Revisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis.International journal of molecular sciences · 2019Review
- Tri-Toxicology research · 2016Article
- Emerging role of liver X receptors in cardiac pathophysiology and heart failure.Basic research in cardiology · 2016Review
- Sirtuin 1 regulates SREBP-1c expression in a LXR-dependent manner in skeletal muscle.PloS one · 2012Article
- SREBP-1 transcription factors regulate skeletal muscle cell size by controlling protein synthesis through myogenic regulatory factors.PloS one · 2012Article
- Article
- Metabolic switching of human myotubes is improved by n-3 fatty acids.Journal of lipid research · 2010Article
- Activation of LXR increases acyl-CoA synthetase activity through direct regulation of ACSL3 in human placental trophoblast cells.Journal of lipid research · 2010Article
- The effects of an in utero exposure to 2,3,7,8-tetrachloro-dibenzo-p-dioxin on male reproductive function: identification of Ccl5 as a potential marker.International journal of andrology · 2010Article
- A new role for sterol regulatory element binding protein 1 transcription factors in the regulation of muscle mass and muscle cell differentiation.Molecular and cellular biology · 2010Article
- Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance.Cardiovascular diabetology · 2009Article
- The Randle cycle revisited: a new head for an old hat.American journal of physiology. Endocrinology and metabolism · 2009Review
- Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.Diabetes · 2008Article
- Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients.Diabetologia · 2008Article
- Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals.Diabetologia · 2007Article
- Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression.Diabetologia · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThe aim of this study was to investigate the effects of liver X receptor (LXR) activation on lipid metabolism and insulin action in human skeletal muscle cells prepared from control subjects and from patients with type 2 diabetes. SUBJECTS AND
methodsCultured myotubes were obtained from muscle biopsies of 11 lean, healthy control subjects and ten patients with type 2 diabetes. The mRNA levels of LXR isoforms and lipogenic genes were estimated by RT-quantitative PCR, and the effects of LXR agonists on insulin action were evaluated by assays of protein kinase B serine 473 phosphorylation and glycogen synthesis.
resultsBoth LXRalpha and LXRbeta were expressed in human skeletal muscle and adipose tissue and there was no difference in their mRNA abundance in tissues from patients with type 2 diabetes compared with control subjects. In cultured muscle cells, LXR activation by T0901317 strongly increased expression of the genes encoding lipogenic enzymes, including sterol regulatory element binding protein 1c, fatty acid synthase and stearoyl-CoA desaturase 1, and also promoted triglyceride accumulation in the presence of a high glucose concentration. Importantly, these effects on lipid metabolism did not affect protein kinase B activation by insulin. Furthermore, LXR agonists did not modify insulin action in muscle cells from patients with type 2 diabetes. CONCLUSIONS/
interpretationThese data suggest that LXR agonists may lead to increased utilisation of lipids and glucose in muscle cells without affecting the mechanism of action of insulin. However, the long-term consequences of triglyceride accumulation in muscle should be evaluated before the development of effective LXR-based therapeutic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.